Adjuvant is a new type of investment firm. We finance the most promising life science technologies for high-burden public health challenges. We see enormous opportunity in historically overlooked market segments, and we leverage our unique expertise to translate these opportunities into social and financial returns for our investors.
Our mission is simple: invest in the most promising public health technologies and ensure they are made accessible to those who need them most. We invest in innovative technologies to address high-burden and neglected infectious diseases, maternal and child health, and reproductive and sexual health. Within the infectious disease category, we focus on the "big three" (HIV/AIDS, tuberculosis, malaria), tropical diseases like schistosomiasis and onchocerciasis, pandemic threats such as Middle East Respiratory Syndrome (MERS) and Lassa fever, and anti-microbial resistance (AMR). The majority of our investment activity is built upon commercializing technologies that have demonstrated safety and efficacy in humans, with the goal of accelerating the global availability of the most impactful medical innovations.
Healthcare spending in emerging economies is one of the fastest growing sectors in the world. Global economic growth is moving billions of people into the middle class, while the call for universal health equity is driving more resources than ever to healthcare for low-income populations. Despite these trends, life sciences investment in this large and growing segment is remarkably low. Our unique focus targets innovations poised to deliver unprecedented health outcomes in underserved markets with the goal of generating truly differentiated "double-bottom-line" returns for our investors.